A gene therapy medicinal product is a medicinal product for advanced therapies whose active substance contains or consists of a recombinant nucleic acid. It is administered to humans to regulate, repair, add, or delete a genetic sequence, and its effect is directly related to this recombinant nucleic acid. The term thus describes a legally defined ATMP category, not every treatment of a genetically caused disease.<\/p>\n
Regulation (EC) No 1394\/2007 classifies gene therapy medicinal products as advanced therapy medicinal products. The EMA describes them as medicinal products containing genes that exert a therapeutic, prophylactic, or diagnostic effect as a result. What matters, therefore, is neither the disease nor the route of administration, but the nature and function of the active substance. A recombinant gene produced in the laboratory can combine different DNA sources and is introduced into the body so that it mediates the intended effect.<\/p>\n
The specific definition excludes medicinal products that constitute a vaccine against infectious diseases. It also requires that the effect be linked to the recombinant nucleic acid itself. For regulatory assessment, labels such as “gene-based” or “personalized” are not sufficient: composition, mechanism of action, and application must be coherently brought together in the product description.<\/p>\n
For a gene therapy medicinal product, the quality documentation links the identity of the nucleic acid, the delivery system used, and batch control with the clinical development program. The EMA guideline requires that quality, non-clinical studies, and clinical data be considered on a product-specific basis. For investigational medicinal products, a classical chemical active substance concept therefore cannot simply be applied.<\/p>\n
In the clinical part, the biological consequences of gene transfer are the main focus. The protocol must define the study population, dosing rationale, safety monitoring, and endpoints in a way that allows the effect of the nucleic acid to be assessed. For products involving genetically modified cells, requirements for advanced therapy medicinal products and for genetically modified organisms also apply together.<\/p>\n
The gene therapy medicinal product is one of three main categories under the umbrella term advanced therapy medicinal products. Somatic cell therapy medicinal products are based on cells or tissue whose biological characteristics have been altered or that are intended to fulfil a different essential function in the recipient. Tissue-engineered products, by contrast, contain engineered cells or tissue for the regeneration, repair, or replacement of human tissue.<\/p>\n
The distinction therefore does not follow a hierarchy, but the legal nature of the product. A product may contain both cellular components and a recombinant nucleic acid at the same time; its classification then requires an assessment of the specific active substance. Biotechnology refers to a much broader field, while a biosimilar refers to a reference medicinal product and does not constitute an ATMP category.<\/p>\n
The ATMP classification also has implications for the regulatory pathway: according to the EMA, all advanced therapy medicinal products are authorized centrally. For early development, the CAT can issue a scientific recommendation on whether a product meets the ATMP criteria. This recommendation does not constitute a full quality, safety, or efficacy assessment, but it prevents a program from being built on an incorrect product assumption. Product characterization should therefore make clear whether the nucleic acid regulates, repairs, adds, or deletes the genetic sequence and how the therapeutic effect follows from this. Depending on the product, the EMA guideline also requires a link between the nucleic acid, the vector or carrier system, and the non-clinical and clinical studies. Such relationships must remain consistent throughout the entire development process.<\/p>\n
In a study involving a gene therapy medicinal product, the CMC documentation, study protocol, and safety monitoring must reflect the same product identity. Particularly important are the traceability of the manufacturing process, the matching of administered batches to study participants, and the recording of events related to the expected biological mechanism of action. The study site requires clear instructions for storage, preparation, administration, and sample collection.<\/p>\n
Full-service CROs such as Mediconomics support the regulatory classification of the investigational medicinal product, the translation of product-specific risks into inclusion and exclusion criteria, and the planning of safety data collection. They coordinate the interfaces between regulatory affairs, clinical project management, monitoring, data management, and medical writing, so that manufacturing information, administration data, and clinical findings appear consistently in the application and in the clinical study report.<\/p>\n
Is every therapy for a hereditary disease a gene therapy medicinal product?<\/strong><\/p>\n No. The legal category depends on whether the active substance meets the characteristics of a medicinal product containing a recombinant nucleic acid and whether its effect is linked to this. The diagnosis of the person being treated is not sufficient for classification.<\/p>\n Why are vaccines against infectious diseases excluded?<\/strong><\/p>\n The ATMP definition for gene therapy medicinal products explicitly excludes such vaccines. A product containing genetic material is therefore not automatically classified as a gene therapy medicinal product merely because of this component.<\/p>\n Who assesses ATMP classification in the EU?<\/strong><\/p>\n The Committee for Advanced Therapies at the EMA can, upon request, issue a scientific recommendation on ATMP classification. This recommendation helps developers identify the appropriate regulatory pathway at an early stage.<\/p>\n A gene therapy medicinal product is a medicinal product for advanced therapies whose active substance contains or consists of a recombinant nucleic acid. It is administered to humans to regulate, repair, add, or delete a genetic sequence, and its effect is directly related to this recombinant nucleic acid. The term thus describes a legally defined […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[30],"class_list":["post-8177","glossary","type-glossary","status-publish","hentry","glossary-cat-atmp-onkologie"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8177","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8177\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=8177"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=8177"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory References<\/h2>\n
\n